| dc.contributor.author | Dobson, R | |
| dc.contributor.author | Baker, D | |
| dc.contributor.author | Kang, A | |
| dc.contributor.author | Schmierer, K | |
| dc.contributor.author | Giovannoni, G | |
| dc.date.accessioned | 2021-10-22T15:42:16Z | |
| dc.date.available | 2021-10-18 | |
| dc.date.available | 2021-10-22T15:42:16Z | |
| dc.identifier.issn | 0364-5134 | |
| dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/74690 | |
| dc.description.abstract | The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple sclerosis (MS). | |
| dc.publisher | Wiley | en_US |
| dc.relation.ispartof | Annals of Neurology | |
| dc.rights | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | |
| dc.title | COVID-19 vaccine response in people with multiple sclerosis | en_US |
| dc.type | Article | en_US |
| dc.rights.holder | © 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. | |
| pubs.notes | Not known | en_US |
| pubs.publication-status | Accepted | en_US |
| dcterms.dateAccepted | 2021-10-18 | |
